JP2019536457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536457A5 JP2019536457A5 JP2019529204A JP2019529204A JP2019536457A5 JP 2019536457 A5 JP2019536457 A5 JP 2019536457A5 JP 2019529204 A JP2019529204 A JP 2019529204A JP 2019529204 A JP2019529204 A JP 2019529204A JP 2019536457 A5 JP2019536457 A5 JP 2019536457A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- recombinant
- cells
- mouse
- immunodeficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000699666 Mus <mouse, genus> Species 0.000 claims 25
- 238000000034 method Methods 0.000 claims 15
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 14
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 14
- 210000000265 leukocyte Anatomy 0.000 claims 10
- 241000699670 Mus sp. Species 0.000 claims 9
- 210000004881 tumor cell Anatomy 0.000 claims 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 6
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 4
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 4
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims 4
- 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 102000053925 human CSF1 Human genes 0.000 claims 4
- 102000055151 human KITLG Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 102000056982 human CD33 Human genes 0.000 claims 1
- 102000052624 human CXCL8 Human genes 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 229940116886 human interleukin-6 Drugs 0.000 claims 1
- 238000011577 humanized mouse model Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022166015A JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428131P | 2016-11-30 | 2016-11-30 | |
| US62/428,131 | 2016-11-30 | ||
| US201762565783P | 2017-09-29 | 2017-09-29 | |
| US62/565,783 | 2017-09-29 | ||
| PCT/US2017/063948 WO2018102546A1 (en) | 2016-11-30 | 2017-11-30 | Humanized mouse model with improved human innate immune cell development |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166015A Division JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536457A JP2019536457A (ja) | 2019-12-19 |
| JP2019536457A5 true JP2019536457A5 (enExample) | 2021-01-21 |
| JP7458185B2 JP7458185B2 (ja) | 2024-03-29 |
Family
ID=60935945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529204A Active JP7458185B2 (ja) | 2016-11-30 | 2017-11-30 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
| JP2022166015A Pending JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166015A Pending JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190320633A1 (enExample) |
| EP (1) | EP3547831A1 (enExample) |
| JP (2) | JP7458185B2 (enExample) |
| CN (1) | CN110740641A (enExample) |
| WO (1) | WO2018102546A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7458185B2 (ja) * | 2016-11-30 | 2024-03-29 | ザ ジャクソン ラボラトリー | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
| SG10202112528QA (en) | 2017-05-12 | 2021-12-30 | Jackson Lab | Nsg mice lacking mhc class i and class ii |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| US20210355501A1 (en) * | 2018-09-24 | 2021-11-18 | Albert Einstein College Of Medicine | Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof |
| US20220192166A1 (en) * | 2019-03-28 | 2022-06-23 | Central Institute For Experimental Animals | Immunodeficient rodent |
| US20220312749A1 (en) * | 2019-08-09 | 2022-10-06 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| CN111705082A (zh) * | 2020-04-14 | 2020-09-25 | 澎立生物医药技术（上海）有限公司 | 具有髓系免疫细胞的人源化免疫系小鼠的构建方法 |
| JP7776486B2 (ja) * | 2020-07-08 | 2025-11-26 | ザ ジャクソン ラボラトリー | ヒトｈｌａ－ａ２０１制限遺伝子を発現するトランスジェニックマウスモデル |
| JP2023542539A (ja) | 2020-09-24 | 2023-10-10 | ザ ジャクソン ラボラトリー | 免疫細胞療法を評価するためのヒト化マウスモデル |
| CN114853871B (zh) * | 2021-04-20 | 2024-04-05 | 百奥赛图(北京)医药科技股份有限公司 | Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用 |
| CN118647724A (zh) * | 2021-12-22 | 2024-09-13 | 杰克逊实验室 | 人源化小鼠模型 |
| AU2023299296A1 (en) | 2022-06-30 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| KR20250067149A (ko) * | 2022-09-08 | 2025-05-14 | 더 잭슨 래보라토리 | 인간화 면역결핍 마우스 모델 |
| EP4608969A1 (en) * | 2022-10-25 | 2025-09-03 | Lapix Therapeutics, Inc. | Immune cell-engrafted non-human animals and non-human animal models |
| WO2025041060A1 (en) * | 2023-08-21 | 2025-02-27 | VeraVerse Co., Ltd. | Patient-derived xenograft model of cancer, preparation method thereof and an apparatus and a method for analyzing drug responsiveness using the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382383A1 (en) * | 1999-08-31 | 2001-03-08 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| RU2577978C2 (ru) * | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| NZ746089A (en) | 2012-09-07 | 2020-05-29 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
| ES2748662T3 (es) * | 2012-11-05 | 2020-03-17 | Institute For Res In Biomedicine Irb | Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| US20150282460A1 (en) | 2014-04-04 | 2015-10-08 | Crown Bioscience Inc. (Taicang) | Animal model with human immune system |
| KR102821645B1 (ko) * | 2014-05-19 | 2025-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| SG10202103445QA (en) | 2015-04-13 | 2021-05-28 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
| JP6654001B2 (ja) | 2015-05-27 | 2020-02-26 | 公益財団法人実験動物中央研究所 | ヒトｉｌ−１５分泌免疫不全マウス |
| TWI810145B (zh) | 2015-06-23 | 2023-08-01 | 杰克森實驗室 | 具有病患衍生之異種移植物之非ｈｌａ配對的人源化ｎｓｇ小鼠模式 |
| CN108471732A (zh) | 2015-10-30 | 2018-08-31 | 杰克逊实验室 | 与肿瘤分析相关的组合物和方法 |
| EP3532493B1 (en) | 2016-10-27 | 2023-04-26 | The Jackson Laboratory | Genetically modified mouse model for human hepatocyte xenotransplantation |
| JP7458185B2 (ja) * | 2016-11-30 | 2024-03-29 | ザ ジャクソン ラボラトリー | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
| AU2018291497A1 (en) * | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| IL272475B2 (en) | 2017-08-09 | 2025-05-01 | Jackson Lab | Immunodeficient mice expressing interleukin 15 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020092655A1 (en) | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
-
2017
- 2017-11-30 JP JP2019529204A patent/JP7458185B2/ja active Active
- 2017-11-30 WO PCT/US2017/063948 patent/WO2018102546A1/en not_active Ceased
- 2017-11-30 EP EP17825653.3A patent/EP3547831A1/en active Pending
- 2017-11-30 US US16/465,006 patent/US20190320633A1/en not_active Abandoned
- 2017-11-30 CN CN201780083557.8A patent/CN110740641A/zh active Pending
-
2022
- 2022-10-17 JP JP2022166015A patent/JP2023015064A/ja active Pending
-
2024
- 2024-06-28 US US18/758,838 patent/US12409237B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536457A5 (enExample) | ||
| Mian et al. | Advances in human immune system mouse models for studying human hematopoiesis and cancer immunotherapy | |
| DuPre et al. | The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci | |
| Hanazawa et al. | Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice | |
| Billerbeck et al. | Development of human CD4+ FoxP3+ regulatory T cells in human stem cell factor–, granulocyte-macrophage colony-stimulating factor–, and interleukin-3–expressing NOD-SCID IL2Rγnull humanized mice | |
| McCaughtry et al. | Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus | |
| JP2022105531A (ja) | 遺伝学的に修飾された非ヒト動物およびその使用法 | |
| Wu et al. | Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets | |
| EP3475413B1 (en) | Genetically modified t lymphocytes | |
| JP2018201521A (ja) | 遺伝子改変されたマウスおよび移植方法 | |
| US20190167720A1 (en) | Gene editing for immunological destruction of neoplasia | |
| CN118813544A (zh) | 遗传修饰的自然杀伤细胞 | |
| JP2012531896A5 (enExample) | ||
| Domaica et al. | Human Natural Killer Cell Maturation Defect Supports In Vivo CD56bright to CD56dim Lineage Development | |
| US20220226379A1 (en) | Dnmt3a knock-out stat5 activated genetically engineered t-cells | |
| Stacey et al. | IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection | |
| Takahashi et al. | Enhanced antibody responses in a novel NOG transgenic mouse with restored lymph node organogenesis | |
| Li et al. | Thymic selection pathway regulates the effector function of CD4 T cells | |
| Scherger et al. | Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma | |
| Morokawa et al. | Autologous non‐human primate model for safety assessment of piggyBac transposon‐mediated chimeric antigen receptor T cells on granulocyte–macrophage colony‐stimulating factor receptor | |
| Prlic et al. | Dissociating markers of senescence and protective ability in memory T cells | |
| US11725187B2 (en) | Selection of human hematopoetic stem cells using EPCR | |
| Ishikawa | Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation | |
| KR102581970B1 (ko) | 면역 부전 마우스 | |
| Powell et al. | SCID pigs: An emerging large animal NK model |